Roche’s proBNP
This article was originally published in The Gray Sheet
Executive Summary
The firm's Elecsys cardiac marker assay is the first natriuretic peptide test cleared by FDA for risk assessment of cardiac events for people with stable coronary artery disease, Roche announces Jan. 3. "Since this is an early marker of cardiac involvement in these disease processes, once a person is identified to be at cardiac risk, they can work with their physician to determine the best treatment and therapy early on," Roche Diagnostics Chief Medical Officer Mike Samoszuk said Jan. 3. ProBNP assays, also available on Dade Behring's Stratus system, have been cleared for aiding congestive heart failure (CHF) diagnosis and as a risk marker for patients with acute coronary syndrome and CHF...